Evotec and Fraunhofer Institute enter joint drug discovery alliance

They will combine their technologies in several disease areas

Evotec has entered into an exclusive collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas using a combination of technology from both organisations.

The alliance expands Evotec's drug discovery platform with access to a range of platforms and capabilities to use on its own projects and for customers and partners.

The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European ScreeningPort into the IME to form the first Fraunhofer life science institution in Hamburg.

Dr Werner Lanthaler, Chief Executive of Evotec, said: 'We are looking forward to partner with Fraunhofer IME and are excited about the potential of this alliance. The IME has an impressive track record for product development and provides an ideal basis for collaborating with one of the strongest science organisations in Germany and beyond. This adds another footprint in Europe of our EVT Innovate programmes as we have with US based academic institutions.'

Companies